Although gemcitabine (GEM) and evofosfamide as monotherapy has a weak effect on MIA Paca-2 and SU 86.86 pancreatic ductal adenocarcinomas respectively, yet the combination therapy shows synergistic effect on both tumor models. The purpose of this study is to understand the synergistic effects of combination therapy using multi-modal imaging methods. In MIA Paca-2 tumors, treatment with GEM induced hypoxia in tumor microenvironment by decreasing the perfusion, which can potentiate evofosfamide. On the other hand, in SU.86.86 tumors, evofosfamide increased blood volume and pO2 in the tumor microenvironment, to potentiate efficacy of anti-proliferatives such as GEM.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords